Easywell Biomedicals, Inc. (TPEX:1799)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
38.40
+0.35 (0.92%)
Apr 29, 2026, 9:30 AM CST
-32.28%
Market Cap 4.74B
Revenue (ttm) 597.41M
Net Income (ttm) -73.14M
Shares Out 124.69M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,002
Average Volume 294,423
Open 38.10
Previous Close 38.05
Day's Range 38.05 - 38.40
52-Week Range 27.65 - 68.30
Beta -0.06
RSI 45.98
Earnings Date May 12, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 1799
Full Company Profile

Financial Performance

In 2025, Easywell Biomedicals's revenue was 597.41 million, an increase of 10.54% compared to the previous year's 540.44 million. Losses were -73.14 million, -24.96% less than in 2024.

Financial Statements

News

There is no news available yet.